title: [A Case of Unresectable Advanced Rectal Cancer with a Pancreatic Tumor That Was Successfully Treated with FOLFIRINOX].
abstract: A 72-year-old man was admitted to our hospital department in September 2014 because of a positive fecal occult blood test.Colonoscopy showed a type 2 tumor in half of the AV 15 cm rectosigmoid colon.Histology of the biopsy indicated a moderately differentiated adenocarcinoma, and the RAS gene test found wild type.On CT examination, there were multiple liver lung metastases and a 30mm diameter tumor with pancreatic duct extension to the pancreatic body.A PET-CT examination had a high SUVmax at the same site.Because of the location of the tumor EUS-FNA was not used.However, the possibility of pancreatic body cancer could not be denied after the CT examination.Treatment by radical resection was impossible because of the spread of the cancer so we selected chemotherapy.Undeniable pancreatic metastasis of rectal cancer, pancreatic cancer was used as a prognostic factor as double cancer of rectal cancer and pancreatic cancer, from that UGT1A1 test side effects appearance was a low-risk decision, was selected FOLFIRINOX in the treatment regimen.After 25 cycles, the pancreatic body tumor and liver metastases and also the primary tumor were reduced, the multiple lung metastases disappeared, and disease control was good.Side effects were diarrhea on the day of administration of irinotecan, but this was controllable by administering oral loperamide when starting the infusion.Grade 3 or more peripheral neuropathy has not developed, and this regimen is continuing.Pancreatic cancer is a solid cancer with a poor prognosis; if you do not reach the tissue diagnosis of metastatic pancreatic cancer, was a case in which no choice but to select a regimen to carcinoma of the prognostic.
authors.affiliation: Dept. of Surgery, Ogikubo Hospital.
authors.forename: Nobushige
authors.initials: N
authors.lastname: Yabe
authors.forename: Shinji
authors.initials: S
authors.lastname: Murai
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ozawa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yokose
authors.forename: Ippei
authors.initials: I
authors.lastname: Oto
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kitasato
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Shimizu
authors.forename: Kenji
authors.initials: K
authors.lastname: Kojima
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome